aemd aethlon medical july investor powerpoint presentation
DESCRIPTION
AEMD Aethlon Medical July Investor PowerPoint Presentation used at RedChip's 2010 NY Midsummer Elite Equities Conference.TRANSCRIPT
![Page 1: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/1.jpg)
JIM JOYCECHAIRMAN, CEO
REDCHIP EQUITIES CONFERENCENASDAQ MARKETPLACE
July 21, 2010
![Page 2: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/2.jpg)
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.
Forward looking statements
![Page 3: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/3.jpg)
IF YOU HAVE CANCER…………
![Page 4: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/4.jpg)
CREATING REVOLUTIONARY DEVICESTHAT ADDRESS INFECTIOUS DISEASE& CANCER
![Page 5: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/5.jpg)
CHANGE THE WAY PEOPLE THINK ABOUT TREATING INFECTIOUS DISEASE & CANCER
![Page 6: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/6.jpg)
THE FIRST MEDICAL DEVICE TO SELECTIVELY FILTER VIRUSES AND IMMUNOSUPPRESSIVE PARTICLES FROM CIRCULATION
THE HEMOPURIFIER®
![Page 7: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/7.jpg)
Leveraging Established Infrastructure
![Page 8: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/8.jpg)
Selectively Targets the Removal of:
![Page 9: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/9.jpg)
![Page 10: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/10.jpg)
The Most Advanced Broad-Spectrum Countermeasure
Bioterror & Pandemic Threats
![Page 11: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/11.jpg)
Virus CollaboratorsHuman Variety
Ebola CDC / USAMRIID YES
Dengue NIV / WHO YES
Lassa SFBR YES
West Nile Battelle YES
H5N1 Avian Battelle YES
Spanish Flu of 1918-R Battelle YES
2009 H1N1 Swine Battelle YES
Monkey pox Battelle NO
![Page 12: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/12.jpg)
OUR HEMOPURIFIER® IS THEONLY TREATMENT STRATEGY TO ADDRESS DRUG RESISTANT AIDS PATIENTS
Human Immunodeficiency Virus (HIV)
![Page 13: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/13.jpg)
DO HIV INFECTED INDIVIDUALS HAVE TO DIE WHEN THEY NO LONGER RESPOND TO THEIR MEDS?
![Page 14: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/14.jpg)
IN THE ABSENCE OF DRUG THERAPY
![Page 15: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/15.jpg)
HIV/AIDS Patient Data
92% reduction of viral load Improved CD4+ T-cell %
30 DAY STUDY – THREE HEMOPURIFIER® TREATMENTS PER WEEK
AIDS
![Page 16: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/16.jpg)
TO ACCELERATE EARLY VIRAL LOAD REDUCTION OF HCV STANDARD OF CARE (SOC) DRUG THERAPY
Hepatitis-C Virus (HCV)
![Page 17: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/17.jpg)
CAN SELECTIVE VIRAL FILTRATION IMPROVE HCV CURE RATES?
![Page 18: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/18.jpg)
IN THE ABSENCE OF DRUG THERAPY
![Page 19: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/19.jpg)
5 Day HCV Treatment Studies
ONE WEEK STUDY – THREE HEMOPURIFIER® TREATMENTS
![Page 20: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/20.jpg)
Validation for Viral Filtration Therapy
Success %
![Page 21: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/21.jpg)
HEMOPURIFIER®+ TELAPRIVIR+ INTERFERON-RIBAVIRIN (SOC)= ____% SVR?
![Page 22: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/22.jpg)
An Enduring Adjunct Opportunity
Hemopurifier® + Current SOC Hemopurifier® + Future Iterations
of SOC 65 drugs in competition
![Page 23: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/23.jpg)
IF YOU HAVE CANCER…………
![Page 24: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/24.jpg)
EXOSOMES ARE SECRETED BY ALL TUMORS, LYMPHOMAS, & LEUKEMIAS
![Page 25: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/25.jpg)
Exosomes are Immunosuppressive
Induce Apoptosis Disrupt T-Cell Signaling Inhibit Cytokine Production Angiogenesis Metastasis
![Page 26: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/26.jpg)
Tumor-Secreted Exosomes
![Page 27: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/27.jpg)
WE ARE AT THE FOREFRONT OF THE EMERGING CANCER EXOSOME FIELD
![Page 28: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/28.jpg)
Full-Spectrum Cancer Opportunity
![Page 29: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/29.jpg)
ARE EXOSOMES PRESENT?
Diagnosis of Cancer
![Page 30: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/30.jpg)
WHAT QUANTITY OF EXOSOMES ARE PRESENT IN BLOOD?
Monitoring Cancer Progression
![Page 31: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/31.jpg)
Enzyme Linked Lectin Specific Assay
ELLSA
![Page 32: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/32.jpg)
REMOVE THE PRESENCE OF IMMUNOSUPPRESSIVE EXOSOMES
Cancer Therapy
![Page 33: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/33.jpg)
OUR HEMOPURIFIER® IS THE SOLE THERAPEUTIC STRATEGY TO ADDRESS IMMUNSUPPRESSIVE EXOSOMES
![Page 34: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/34.jpg)
MAXIMIZING THE ABILITY OF THE IMMUNE SYSTEM TO COMBAT CANCER?
![Page 35: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/35.jpg)
A Complementary Therapeutic
Targets Benefit w/o Stacking additional drug
toxicity Adding drug interaction risk
![Page 36: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/36.jpg)
DOES THE MEDICAL COMMUNITY HAVE INTEREST IN EXOSOMES?
![Page 37: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/37.jpg)
Interest in Exosomes
![Page 38: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/38.jpg)
DOES THE MEDICAL COMMUNITY HAVE INTEREST IN AETHLON MEDICAL?
![Page 39: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/39.jpg)
>600
![Page 40: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/40.jpg)
Push vs. Pull
![Page 41: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/41.jpg)
ADVANCING COLLABORATIVE RELATIONSHIPS WITH THOUGHT LEADERS REPRESENTING PREMIER CANCER TREATMENT INSTITUTES
![Page 42: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/42.jpg)
![Page 43: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/43.jpg)
![Page 44: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/44.jpg)
A Foundation to Build Value
![Page 45: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/45.jpg)
![Page 46: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/46.jpg)
www.npr.org/templates/story/story.php?storyId=128339775
![Page 47: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/47.jpg)
Guidance DisclosureRemainder of 2010
![Page 48: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/48.jpg)
Remainder of 2010 Guidance
Infectious Disease Initiate Medanta-Medicity HCV
adjunct treatment studies (establish revenue stream)
Increase treatment site opportunities Define clinical plans beyond India
Cancer Data from multiple studies
Hemopurifier® & ELLSA Disclosure of collaborative partners Define U.S. clinical programs
![Page 49: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/49.jpg)
CREATING REVOLUTIONARY DEVICESTHAT ADDRESS INFECTIOUS DISEASE& CANCER
![Page 50: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/50.jpg)
CHANGE THE WAY PEOPLE THINK ABOUT TREATING INFECTIOUS DISEASE & CANCER
![Page 51: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/51.jpg)
AEMD
![Page 52: AEMD Aethlon Medical July Investor PowerPoint Presentation](https://reader038.vdocuments.us/reader038/viewer/2022110114/5466216faf7959e5108b465f/html5/thumbnails/52.jpg)
JIM JOYCECHAIRMAN, CEO
8910 UNIVERSITY CENTER LANESAN DIEGO, CA. 92122
[email protected] X301
ASSISTANT: CHARLENE [email protected] X305